Navigation Links
Boiron Laboratories Disputes British Journal's Editorial on Homeopathy
Date:11/27/2007

NEWTOWN SQUARE, Pa., Nov. 27 /PRNewswire/ -- In its continued educational and research efforts for the advancement of homeopathy, Boiron Laboratories disputes an editorial comment published in The Lancet's Nov. 17, 2007 issue on the basis that its author has misinterpreted results of clinical trials on homeopathic medicines. (1-5)

The British medical journal features an editorial by Ben Goldacre on the "Benefits and Risks of Homeopathy." In his commentary, Goldacre suggests that the results from five large meta-analyses indicate that homeopathy produces no statistically significant benefit over placebo.

However, a thorough review of the studies' research evidence indicates positive principle conclusions in favor of homeopathy over placebo as quoted as follows:

1. The Kleijnen, et al(1) study states that "the evidence of clinical

trials is positive but not sufficient to draw any definite

conclusions."

2. The Boissel, et al(2) study reports that "[f]or 17 retained

comparisons, for each method used, the result is a p-value well below

.0001. This means that in at least one test, the null hypothesis (lack

of effect of homeopathy) must be rejected. ... The number of

significant results is not likely due to chance alone."

3. The Linde, et al(3) study concludes that "[t]he results of the

available randomized trials suggest that individualized homeopathy has

an effect over placebo."

4. The Cucherat, et al(4) study concludes that "[t]here is evidence that

homeopathic treatments are more effective than placebo."

5. The Shang, et al(5) study indicates that "21 (19 percent) homeopathic

trials and nine (8 percent) conventional medicine tests were of higher

quality. Most odds ratios indicated a beneficial effect of the

intervention. Heterogeneity of trial results was less pronounced for

homeopathy ... than conventional medicine .... This difference is

unlikely to be due to chance (p=0.011 by F test)."

Additionally, there is a sixth relevant meta-analysis(6) also published in The Lancet that supports positive results for homeopathy, but was not mentioned in Goldacre's commentary. The study authors concluded that "the results of our meta-analysis are not compatible with the hypothesis that the clinical effects of homeopathy are completely due to a placebo effect."

About Boiron: Boiron, world leader in homeopathy, is a $500 million public company with 3,800 employees in more than 60 countries. It produces more than 1,500 homeopathic medicines. For over 70 years, Boiron has been committed to funding scientific research and educating the public and healthcare professionals on homeopathic medicines. Boiron maintains the highest manufacturing standards, complying with U.S. Food and Drug Administration regulations, the Homeopathic Pharmacopoeia of the United States and drug Good Manufacturing Practices.

References

1. Kleijnen J, Knipschild P, ter Riet G. Clinical trials of homeopathy.

BMJ 1991; 302: 316-23.

2. Boissel JP, Cucherat M, Haugh M, Gauthier E. Critical literature review

on the effectiveness of homoeopathy: overview of data from homeopathic

medicine trials. Brussels, Belgium: Homoeopathic Medicine Research

Group. Report to the European Commission. 1996; 195-210.

3. Linde K, Melchart D. Randomized controlled trials of individualized

homeopathy: a state-of-the-art review. J Alter Complement Med 1998;

4: 371-88.

4. Cucherat M, Haugh MC, Gooch M, Boissel JP. Evidence of clinical

efficacy of homeopathy: a meta-analysis of clinical trials. Eur JClin

Pharmacol 2000; 56: 27-33.

5. Shang A, Huwiler-Muntener K, Nartey L, et al. Are the clinical effects

of homeopathy placebo effects? Comparative study of placebo-controlled

trials of homeopathy and allopathy. The Lancet 2005; 366: 726-32.

6. Linde K, Clausius N, Ramirez H, et al. Are the clinical effects of

homeopathy placebo effects? A meta-analysis of placebo-controlled

trials. The Lancet 1997; 350: 834-43. Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Ronald Boyer, M.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=58078 Christophe Merville http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=56842


'/>"/>
SOURCE Boiron Laboratories
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
5. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
6. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
7. Mesa Laboratories Names New Vice President of Sales and Marketing
8. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. JDRF partners with Housey Pharmaceutical Research Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company of ... employee engagement. Omaha-based C&A Industries, a national leader in staffing and recruitment, ... in North America for 2017. The annual award, issued by Achievers, an ...
(Date:6/28/2017)... ... June 28, 2017 , ... Guide to FDA and ... , No matter on which side of the Atlantic devicemakers do business, this fully ... have to follow. , In addition to the full text of the FDA’s regulations ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest ... minutes, at least one person dies as a direct result from an eating disorder ... for qualified treatment providers. The iaedp Foundation meets this challenge by offering what has ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the ... the award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs ... a regional supplier of garden pea seed. As demand grew, the small company located ...
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance and Financial, a ... in southern Montana, is announcing a focused charity effort to gather regional support ... offered by Zoo Montana provide students with current knowledge on the characteristics and ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
Breaking Medicine Technology: